U.S. markets closed

Axsome Therapeutics, Inc. (AXSM)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
26.46+2.33 (+9.66%)
At close: 04:00PM EDT
26.70 +0.24 (+0.91%)
After hours: 07:53PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected


Previous Close24.13
Bid25.51 x 900
Ask26.50 x 1000
Day's Range23.28 - 26.83
52 Week Range19.38 - 74.10
Avg. Volume1,089,680
Market Cap1.03B
Beta (5Y Monthly)2.47
PE Ratio (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for AXSM

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Axsome Therapeutics, Inc.
    Daily – Vickers Top Buyers & Sellers for 05/26/2022The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Fair Value
    Economic Moat
    2 days agoArgus Research
View more
  • Motley Fool

    2 Under-the-Radar Biotech Stocks to Buy in 2022

    With that as a backdrop, let's consider two biotech stocks that don't grab a lot of headlines but deserve serious consideration: Incyte (NASDAQ: INCY) and Axsome Therapeutics (NASDAQ: AXSM). Incyte is a drugmaker with a particular focus on the field of oncology. Its best-selling product is called Jakafi, which treats some types of bone marrow cancer, among other conditions.

  • Motley Fool

    2 Biotech Stocks That Could Go Parabolic

    Biotech stocks have taken a beating to start the year, with the S&P Biotech Industry Index down more than 49% so far. There are several reasons a biotech stock could go parabolic -- that is, have its shares see a sharp rise in a short period. The company could be the buyout target of a merger deal with a larger pharmaceutical company.

  • Motley Fool

    Is This Biotech a Safe Stock to Buy?

    Upon first glance, Axsome Therapeutics (NASDAQ: AXSM) doesn't exactly sound like a candidate for being a safe stock that's ready to buy today. At present, the biotech has no approved drugs nor any revenue. Its drug AXS-05 is its flagship program, and it's being investigated in a late-stage clinical trial for its usefulness in treating agitation in Alzheimer's disease, as well as in another trial for smoking cessation.